accountwith a weight-negative profile are establishing a place in all phases of the obesity pipeline. Novo Nordisk and Eli Lilly both have glucagon-like peptide-1 agonists (GLP-1s) in development for obesity. The most advanced of which is liraglutide, in Phase...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Reportlinker Adds R&D Trends: Obesity - 2006-2011: obesity's lean years
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account